By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Nanobodies. According to news reporting originating in Ghent, Belgium, by NewsRx journalists, research stated, "Invadopodia are actin-rich protrusions arising through the orchestrated regulation of precursor assembly, stabilization, and maturation, endowing cancer cells with invasive properties. Using nanobodies (antigen-binding domains of Camelid heavy-chain antibodies) as perturbators of intracellular functions and/or protein domains at the level of the endogenous protein, we examined the specific contribution of fascin and cortactin during invadopodium formation in MDA-MB-231 breast and PC-3 prostate cancer cells."
The news reporters obtained a quote from the research from Ghent University, "A nanobody (K(d)~35 nM, 1:1 stoichiometry) that disrupts fascin F-actin bundling emphasizes the importance of stable actin bundles in invadopodium array organization and turnover, matrix degradation, and cancer cell invasion. Cortactin-SH3 dependent WIP recruitment toward the plasma membrane was specifically inhibited by a cortactin nanobody (K(d)~75 nM, 1:1 stoichiometry). This functional domain is shown to be important for formation of properly organized invadopodia, MMP-9 secretion, matrix degradation, and cancer cell invasion. Notably, using a subcellular delocalization strategy to trigger protein loss of function, we uncovered a fascin-bundling-independent role in MMP-9 secretion."
According to the news reporters, the research concluded: "Hence, we demonstrate that nanobodies enable high resolution protein function mapping in cells."
For more information on this research see: Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. The Faseb Journal, 2014;28(4):1805-18 (see also Nanobodies).
Our news correspondents report that additional information may be obtained by contacting I. Van Audenhove, 1Dept. of Biochemistry, Faculty of Medicine and Health Sciences, Ghent University, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium. Additional authors for this research include C. Boucherie, L. Pieters, O. Zwaenepoel, B. Vanloo, E. Martens, C. Verbrugge, G. Hassanzadeh-Ghassabeh, J. Vandekerckhove, M. Cornelissen, A. De Ganck and J. Gettemans.
Keywords for this news article include: Ghent, Europe, Cancer, Belgium, Oncology, Nanobodies, Nanotechnology, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC